Dorian Haskard was an undergraduate at Oxford University before moving to The Middlesex Hospital Medical School and subsequently into a range of clinical and research posts in London and the US. In 1987 he was awarded a Wellcome Trust Senior Clinical Fellowship at UMDS, Guy's Hospital. Following this he was appointed to Senior Clinical Lectureship at the Royal Postgraduate Medical School, Hammersmith Hospital, being promoted to Reader and then to Professor in 1995.
Professor Haskard has previously held the following leadership positions at Imperial College: British Heart Foundation Sir John McMichael Chair of Cardiovascular Medicine (1995-2016); Head of the Vascular Sciences Section within the National Heart and Lung Institute (2014-2017); Head of Division of Immunology and Inflammation in the Department of Medicine (2010-2017); and Head of the Division of Clinical Cardiovascular Science (2017-2018).
Professor Haskard has given numerous prestigious national and international lectures and is member of a number of learned societies and funding charities. Notably he was Chairman of the Arthritis Research Campaign Fellowship Committee (2000-2005) and Chairman of the British Atherosclerosis Society (2008-2010). He is President of the International Society for Behçet’s Disease (President 2016-2010), and serves on the National Anti-Doping Panel (NADP).
He has directly supervised 7 post-docs; 45 completed PhD students and many MSc, MRes and BSc students have performed projects within his personal research group at Imperial College.
The goal of Professor Haskard's research has been to achieve a greater understanding of the pathophysiology of inflammatory responses affecting the vascular system, with a view eventually to achieving more specific clinical diagnostic tests and therapies. Current work focuses on two main areas in relation to the biology of vascular inflammation and atherosclerosis: (i) mechanisms of macrophage and endothelial cell gene expression, with an emphasis on post-transcriptional RNA regulation, and (ii) the role of antibodies and complement.
et al., 2019, An integrated chemical proteomics approach for quantitative profiling of intracellular ADP-Ribosylation, Scientific Reports, Vol:9, ISSN:2045-2322
et al., Comparing the clinical profile of adults and children with Behçet's syndrome in the UK., Clinical and Experimental Rheumatology, ISSN:0392-856X
Hartley A, Dorian H, Khamis RYJ, 2019, Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - novel insights and future directions in diagnosis and therapy, Trends in Cardiovascular Medicine, Vol:29, ISSN:1050-1738, Pages:22-26
et al., 2019, VERTEBRATE HEMATOMA RESOLUTION IS DIRECTED BY ACTIVATING TRANSCRIPTION FACTOR 1 (ATF1) AND ADENOSINE-MONOPHOSPHATE-ACTIVATED-PROTEIN-KINASE (AMPK), 87th Congress of the European-Atherosclerosis-Society (EAS), ELSEVIER IRELAND LTD, Pages:E246-E246, ISSN:0021-9150
et al., 2019, SMARCA4 REDIRECTS BINDING OF MACROPHAGE ACTIVATING TRANSCRIPTION FACTOR 1 (ATF1) FROM GENES FOR INFLAMMATION RESOLUTION TO GENES FOR ERYTHROCYTE RESOLUTION, 87th Congress of the European-Atherosclerosis-Society (EAS), ELSEVIER IRELAND LTD, Pages:E78-E78, ISSN:0021-9150